Compare Stocks: NRC, CERT, GDRX, and TDOC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$9.36 +0.2%	$8.27	$4.45 ▼ $13.88	$1.42B	1.42	2.56 million shs	2.60 million shs
GDRX GoodRx	$3.28 +0.3%	$3.44	$1.77 ▼ $5.81	$1.12B	1.69	808,954 shs	860,463 shs
NRC National Research	$20.35 -4.5%	$21.01	$11.01 ▼ $23.68	$484.95M	0.25	126,381 shs	124,152 shs
TDOC Teladoc Health	$5.54 -2.4%	$6.56	$4.40 ▼ $9.89	$1.03B	2.14	3.16 million shs	4.89 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	+1.52%	+5.06%	+15.31%	+34.00%	-30.14%
GDRX GoodRx	-0.61%	-2.68%	-5.49%	+7.21%	-34.99%
NRC National Research	+0.61%	+4.77%	+4.31%	-4.82%	+70.56%
TDOC Teladoc Health	-2.41%	-7.35%	-9.20%	-38.25%	-27.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$9.36 +0.2%	$8.27	$4.45 ▼ $13.88	$1.42B	1.42	2.56 million shs	2.60 million shs
GDRX GoodRx	$3.28 +0.3%	$3.44	$1.77 ▼ $5.81	$1.12B	1.69	808,954 shs	860,463 shs
NRC National Research	$20.35 -4.5%	$21.01	$11.01 ▼ $23.68	$484.95M	0.25	126,381 shs	124,152 shs
TDOC Teladoc Health	$5.54 -2.4%	$6.56	$4.40 ▼ $9.89	$1.03B	2.14	3.16 million shs	4.89 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	+1.52%	+5.06%	+15.31%	+34.00%	-30.14%
GDRX GoodRx	-0.61%	-2.68%	-5.49%	+7.21%	-34.99%
NRC National Research	+0.61%	+4.77%	+4.31%	-4.82%	+70.56%
TDOC Teladoc Health	-2.41%	-7.35%	-9.20%	-38.25%	-27.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERT Certara	2.42	Hold	$8.45	-9.72% Downside
GDRX GoodRx	2.08	Hold	$4.23	28.88% Upside
NRC National Research	2.50	Moderate Buy	$26.00	27.76% Upside
TDOC Teladoc Health	2.25	Hold	$7.54	36.12% Upside

Current Analyst Ratings Breakdown

Latest NRC, CERT, GDRX, and TDOC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	CERT Certara	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00
9/30/2026	CERT Certara	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/21/2026	NRC National Research	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$3.00 ➝ $4.00
8/19/2026	TDOC Teladoc Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$2.50 ➝ $3.75
8/11/2026	GDRX GoodRx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/11/2026	GDRX GoodRx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/7/2026	GDRX GoodRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/7/2026	GDRX GoodRx	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
8/7/2026	GDRX GoodRx	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$3.50 ➝ $5.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERT Certara	$418.84M	3.41	$0.76 per share	12.34	$6.67 per share	1.40
GDRX GoodRx	$796.85M	1.41	$0.40 per share	8.17	$1.81 per share	1.81
NRC National Research	$137.39M	3.37	$1.20 per share	16.96	$0.62 per share	32.82
TDOC Teladoc Health	$2.53B	0.40	$1.76 per share	3.15	$7.81 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERT Certara	-$1.60M	-$0.45	N/A	33.43	N/A	-16.75%	3.86%	2.65%	11/5/2026 (Estimated)
GDRX GoodRx	$30.44M	$0.04	82.02	16.40	1.63	2.07%	7.22%	2.53%	11/3/2026 (Estimated)
NRC National Research	$11.60M	$0.25	81.40	N/A	N/A	4.18%	164.26%	14.67%	10/26/2026 (Estimated)
TDOC Teladoc Health	-$200.32M	-$0.99	N/A	N/A	N/A	-7.13%	-12.15%	-5.83%	10/28/2026 (Estimated)

Latest NRC, CERT, GDRX, and TDOC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	TDOC Teladoc Health	-$0.2171	N/A	N/A	N/A	$590.46 million	N/A
10/26/2026	Q3 2026	NRC National Research	$0.21	N/A	N/A	N/A	$35.80 million	N/A
8/5/2026	Q2 2026	GDRX GoodRx	$0.0797	$0.08	+$0.0003	$0.02	$193.23 million	$200.41 million
8/4/2026	Q2 2026	CERT Certara	$0.0893	$0.08	-$0.0093	-$0.36	$98.09 million	$93.27 million
7/29/2026	Q2 2026	TDOC Teladoc Health	-$0.2498	-$0.21	+$0.0398	-$0.21	$615.44 million	$606.93 million
7/28/2026	Q2 2026	NRC National Research	-$0.15	$0.31	+$0.46	-$0.15	$34.90 million	$35.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERT Certara	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
NRC National Research	$0.64	3.14%	+19.88%	256.00%	N/A
TDOC Teladoc Health	N/A	N/A	N/A	N/A	N/A

Latest NRC, CERT, GDRX, and TDOC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	NRC National Research	quarterly	$0.16	3.27%	9/25/2026	9/25/2026	10/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERT Certara	0.30	2.55	2.55
GDRX GoodRx	0.74	1.38	1.38
NRC National Research	13.13	0.65	0.65
TDOC Teladoc Health	N/A	0.83	0.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERT Certara	73.96%
GDRX GoodRx	63.77%
NRC National Research	47.26%
TDOC Teladoc Health	76.82%

Insider Ownership

Company	Insider Ownership
CERT Certara	1.08%
GDRX GoodRx	5.87%
NRC National Research	9.20%
TDOC Teladoc Health	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERT Certara	1,576	152.54 million	150.89 million	Optionable
GDRX GoodRx	697	342.57 million	322.47 million	Optionable
NRC National Research	357	22.75 million	20.65 million	Optionable
TDOC Teladoc Health	5,600	181.68 million	180.41 million	Optionable

NRC, CERT, GDRX, and TDOC Headlines

Recent News About These Companies

Teladoc Health stock trades at EUR 5.07 before Xetra opens

September 30 at 8:49 AM | ad-hoc-news.deA

Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know

September 29 at 10:31 PM | finance.yahoo.com

Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know

September 29 at 7:16 PM | zacks.com

Evergreen Nephrology Appoints Brian Palo as Chief Financial Officer

September 28, 2026 | finance.yahoo.com

171,447 Teladoc Health, Inc. $TDOC Shares Sold by Corient Private Wealth LP

September 28, 2026 | marketbeat.com

Teladoc Health Announces Resignation of Chief Legal Officer Adam C. Vandervoort Effective November 1, 2026

September 27, 2026 | kalkinemedia.comK

Head to Head Analysis: Weave Communications (NYSE:WEAV) vs. Teladoc Health (NYSE:TDOC)

September 27, 2026 | americanbankingnews.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)

September 25, 2026 | theglobeandmail.com

Teladoc Health, Inc. Announces Management Changes

September 25, 2026 | marketscreener.comM

Teladoc Health Announces Chief Legal Officer Transition

September 25, 2026 | finance.yahoo.com

Connected Health & Safety Association Annual Conference Highlights Industry Growth and the Future of Connected Care

September 25, 2026 | finance.yahoo.com

Teladoc Announces Chief Legal Officer Leadership Transition

September 25, 2026 | tipranks.com

Teladoc Health stock holds near USD 6.26 as revenue pressure persists

September 25, 2026 | ad-hoc-news.deA

Teladoc Health Announces Chief Legal Officer Transition

September 25, 2026 | globenewswire.com

3 Small-Cap Stocks We Find Risky

September 24, 2026 | finance.yahoo.com

Can Doximity Keep Shrinking Its Share Count Through Its AI Investment Year?

September 24, 2026 | trefis.comT

Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note

September 23, 2026 | finance.yahoo.com

Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note

September 23, 2026 | zacks.com

Health Catalyst (NASDAQ:HCAT) vs. Teladoc Health (NYSE:TDOC) Critical Contrast

September 22, 2026 | americanbankingnews.com

How to Buy Teladoc Stock (TDOC) in 2026

September 21, 2026 | fool.com

Engineers Gate Manager LP Sells 201,521 Shares of Teladoc Health, Inc. $TDOC

September 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRC, CERT, GDRX, and TDOC Company Descriptions

Certara NASDAQ:CERT

$9.36 +0.02 (+0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.09 -0.27 (-2.88%)

As of 07:30 PM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

GoodRx NASDAQ:GDRX

$3.28 +0.01 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.28 +0.01 (+0.15%)

As of 07:30 PM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

National Research NASDAQ:NRC

$20.35 -0.97 (-4.55%)

Closing price 04:00 PM Eastern

Extended Trading

$20.40 +0.05 (+0.25%)

As of 07:30 PM Eastern

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Teladoc Health NYSE:TDOC

$5.54 -0.13 (-2.36%)

Closing price 03:59 PM Eastern

Extended Trading

$5.55 +0.01 (+0.25%)

As of 07:58 PM Eastern

Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRC, CERT, GDRX, and TDOC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRC, CERT, GDRX, and TDOC Earnings

Compare Dividends

Latest NRC, CERT, GDRX, and TDOC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRC, CERT, GDRX, and TDOC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRC, CERT, GDRX, and TDOC Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

National Research NASDAQ:NRC

Teladoc Health NYSE:TDOC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools